Showing results (71-80 of 186) with videos related to

Sort By:
Pageof 19
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 21, 2018
Long-Term Follow-Up of <sup>90</sup>Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell LymphomaCamille E Puronen, Ryan D Cassaday, Philip A Stevenson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2018
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced CancerNeil H Segal, Aiwu R He, Toshihiko Doi, et al.
Cancer Medicine|November 18, 2021
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trialSriram Balasubramanian, Brendan Hodkinson, Stephen J Schuster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research|January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemiaJohn M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 27, 2018
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance TherapyAndrew J Cowan, Philip A Stevenson, Edward N Libby, et al.
Blood|November 29, 2007
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapyJohn M Pagel, Nathan Hedin, Lacey Drouet, et al.
Blood|July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaRobert Chen, Ajay K Gopal, Scott E Smith, et al.
The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.
Leukemia & Lymphoma|December 10, 2020
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomasNina D Wagner-Johnston, Stephen J Schuster, Sven deVos, et al.
Pageof 19